We currently recommend the incorporation of FLT3i’s and ASCT in CR1 in all ASCT eligible patients with a FLT3-ITDmut AML, irrespective of the AR and/or NPM1 co-mutation status. This evidence concerns the gene NPM1 and acute myeloid leukemia.